Supernus v. Zenara Pharma: Qelbree Viloxazine ER Patent Dispute Consolidated
Supernus Pharmaceuticals filed suit in the District of New Jersey against Zenara Pharma Private Limited, asserting six Orange Book patents protecting Qelbree (viloxazine extended-release capsules). After 165 days, the case was consolidated with 13 other ANDA challenger defendants into a unified pretrial proceeding — a scale that underscores the commercial stakes of generic entry into the viloxazine market.
Hatch-Waxman battlefront: Supernus consolidates Qelbree ANDA challenges
Supernus Pharmaceuticals, Inc. filed this action on July 11, 2025 in the U.S. District Court for the District of New Jersey, asserting infringement of six Orange Book-listed patents covering its Qelbree product — viloxazine extended-release capsules available in 100 mg, 150 mg, and 200 mg strengths. Zenara Pharma Private Limited, an India-headquartered generics developer, is one of at least fourteen defendants who filed ANDAs seeking approval to market generic versions of Qelbree before patent expiry.
On December 23, 2025 — following a December 17 Initial Scheduling Conference — the Court entered a consolidation order merging this action with parallel cases against Appco Pharma, Somerset Therapeutics, Apotex, Aurobindo Pharma, Zydus entities, Creckwood Pharmaceuticals, MSN Pharmaceuticals, Biophore Pharma, Macleods Pharmaceuticals, and Macleods Pharma USA. The consolidation is for pretrial purposes only and subjects all parties to a single coordinated schedule. Consolidation does not resolve the merits; Zenara’s ANDA challenge and Supernus’s infringement claims remain live.
The 165-day timeline from filing to consolidation order is consistent with standard Hatch-Waxman scheduling practice, where courts frequently consolidate multiple ANDA defendants early to manage parallel discovery. The breadth of the defendant roster — 14 generic challengers — suggests the Qelbree franchise faces significant near-term generic competition risk. The public record does not yet disclose which specific patent claims each defendant contests, nor whether any defendant has moved for early resolution.
Filing to Case Consolidated in 165 days
165 days from filing to consolidation order — consistent with expedited ANDA scheduling
Case consolidated: what pretrial merger means for Supernus and Zenara
Consolidation combines parallel ANDA suits — merits survive
Under Fed. R. Civ. P. 42(a), courts may consolidate actions sharing common questions of law or fact. Here, all 14 ANDA cases involve the same Orange Book patents and Qelbree product, making a single pretrial schedule the efficient path. Critically, consolidation for pretrial purposes does not dismiss any claim — each defendant’s challenge to the six patents remains pending and will proceed to discovery and, eventually, trial.
FRCP 42(a) pretrial consolidationSupernus gains coordinated enforcement across 14 challengers
Consolidation typically favours the patent holder in multi-defendant ANDA litigation: Supernus can now conduct unified claim construction, coordinate discovery, and present a single set of infringement contentions across all defendants. This reduces litigation cost and the risk of inconsistent rulings on the same patent claims. The 30-month stay on FDA approval of each ANDA remains in place during the consolidated proceedings, preserving Qelbree’s market exclusivity.
30-month stay preservedZenara joins a 14-defendant bloc with shared discovery burden
For Zenara, consolidation means sharing discovery and potentially coordinating invalidity or non-infringement arguments with co-defendants. This can reduce individual legal costs but also limits strategic flexibility — defendants with divergent ANDA formulations may need to balance coalition arguments against product-specific defences. Zenara’s path to generic market entry remains blocked until the consolidated litigation resolves or a court finds the asserted patents invalid or not infringed.
Generic entry blocked pending outcome14-defendant wave signals high generic interest in viloxazine market
The volume of ANDA filers — 14 defendants across consolidated and related cases — is consistent with a commercially significant branded product. Viloxazine ER (Qelbree) is approved for ADHD in paediatric and adult patients, a high-value CNS segment. The consolidated structure suggests the District of New Jersey expects protracted litigation; parties and investors should monitor the lead case schedule (Civil Action No. 25-12183) for bellwether rulings on claim construction and validity.
CNS/ADHD generic competition riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | Specialty CNS pharma company — holder of six Orange Book patents for Qelbree (viloxazine ER)Search in Eureka ↗ |
| Defendant | Zenara Pharma Private, Ltd. | Company | India-based generics developer seeking ANDA approval for viloxazine ER capsulesSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EDGAR H. HAUG | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JONATHAN HERSTOFF | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | KAITLIN M. FARRELL | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | NICHOLAS F. GIOVE | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Frank Kurz | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Haug Partners, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Dmitry V. Shelhoff | Attorney | Counsel for Zenara Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | KENNETH CANFIELD | Attorney | Counsel for Zenara Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant law firm | SHELHOFF CANFIELD & CHIN | Law Firm | Representing Zenara Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant law firm | SHELHOFF CANFIELD & CHIN LLC | Law Firm | Representing Zenara Pharma Private, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a purely procedural ruling: the Court found common questions of law and fact across all 14 ANDA actions sufficient to justify a unified pretrial schedule. No merits determination has been made on infringement or validity of any of the six asserted patents. The order’s reference to the existing Civil Action No. 25-12183 schedule as the governing framework suggests that case is the operative lead, and rulings there will have direct precedential weight for Zenara’s defence.
US12121523B2 and five further Qelbree Orange Book patents — viloxazine ER
The six asserted patents — US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — are listed in the FDA Orange Book for Qelbree (viloxazine hydrochloride extended-release capsules, 100/150/200 mg), Supernus’s non-stimulant ADHD treatment. The application numbers span filings from 2013 through 2022, suggesting a prosecution strategy that added continuation and divisional coverage over time to extend protection into the 2030s across formulation, composition, and therapeutic method claims.
From a competitive intelligence standpoint, a six-patent Orange Book listing with staggered expiry dates is a deliberate lifecycle management structure. Generic challengers face the burden of invalidating or designing around each patent independently, and any surviving patent can block FDA approval. For competitors in the non-stimulant ADHD space — a segment growing in clinical and commercial importance — these patents represent a significant freedom-to-operate barrier. The consolidated litigation outcome will set the precedent for any subsequent generic entrant.
Should you run an FTO against Supernus’s six Qelbree patents?
Any company developing a viloxazine extended-release oral formulation for ADHD — whether as an ANDA filer, a 505(b)(2) applicant, or a reformulation program — should conduct a structured FTO analysis against all six Orange Book-listed patents. The asserted patents cover formulation parameters, composition ratios, and methods of treatment, meaning even a technically distinct ER matrix may face exposure if it produces therapeutically equivalent release profiles. The 14-defendant consolidation confirms that multiple sophisticated generics teams have assessed the risk and proceeded — but also that none has yet prevailed.
PatSnap Eureka’s FTO Search Agent can map each of the six patent claim sets against your formulation parameters, surface relevant prior art that challengers are likely deploying in the consolidated litigation, and flag continuation applications that may introduce new claim coverage. Given the staggered application dates from 2013–2022, a family-level analysis — not just the granted patents — is essential to identify pending continuation risk before committing to an ANDA filing strategy.
Run a freedom-to-operate analysis on US12121523B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: viloxazine and non-stimulant ADHD litigation
Cases involving Orange Book patent assertions for CNS extended-release formulations in D.N.J., with multi-defendant ANDA consolidation patterns comparable to the Qelbree litigation.
What this case signals for the viloxazine and CNS ANDA IP landscape
A 14-defendant consolidation in D.N.J. is a high-stakes signal for the Qelbree franchise and the broader ADHD generics pipeline.
Six-patent Orange Book listing creates a layered invalidation challenge
Supernus asserts six patents across formulation, composition, and method-of-use dimensions. Generic challengers must invalidate or design around all six to achieve clean ANDA approval. This layered portfolio strategy is common in branded CNS drugs and significantly raises the bar for generic entry — each patent represents a separate litigation track and potential 30-month stay.
Lead case No. 25-12183 will drive the consolidated schedule — monitor it closely
The Court anchored the consolidated schedule to Civil Action No. 25-12183. Claim construction rulings and discovery deadlines in that case will bind Zenara and all co-defendants. IP teams tracking viloxazine freedom-to-operate should follow that docket for the first substantive rulings on Supernus’s patent scope.
Supernus v Zenara — key questions answered
Supernus asserted six Orange Book-listed patents: US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2. All relate to Qelbree (viloxazine extended-release capsules, 100/150/200 mg) and cover formulation, composition, and method-of-use aspects of the product.
The Court consolidated the case with 13 parallel ANDA actions involving the same six Orange Book patents and the same Qelbree product. At the December 17, 2025 Initial Scheduling Conference, the Court directed all parties to submit a proposed Consolidation Order, which was entered on December 23, 2025. Consolidation is for pretrial purposes only; all claims remain pending.
No. Consolidation is a procedural mechanism under FRCP 42(a) that merges cases for efficiency. It does not resolve infringement or validity. Zenara’s ANDA challenge and Supernus’s infringement allegations remain live and will proceed under the unified schedule anchored to lead case Civil Action No. 25-12183.
The volume of ANDA filers is consistent with a high-value branded product. Viloxazine ER (Qelbree) is a non-stimulant ADHD treatment in a growing CNS segment. The 14-defendant roster suggests broad generic industry interest and competitive pressure on Supernus’s market exclusivity. Each defendant faces the 30-month stay blocking FDA approval during the consolidated litigation.
Supernus is represented by Haug Partners, LLP and Saul Ewing, LLP, with attorneys including Edgar H. Haug, Jonathan Herstoff, Kaitlin M. Farrell, Nicholas F. Giove, Richard Frank Kurz, and William C. Baton. Zenara Pharma is represented by Shelhoff Canfield & Chin LLC, with attorneys Dmitry V. Shelhoff and Kenneth Canfield.
PatSnap Eureka searches patents and litigation data to answer instantly.